{"title": "Phio Pharmaceuticals Corp (PHIO-Q) Quote - Press Release", "author": "Unknown", "url": "https://www.theglobeandmail.com/investing/markets/stocks/PHIO/pressreleases/17006614/", "hostname": "theglobeandmail.com", "description": "Detailed price information for Phio Pharmaceuticals Corp (PHIO-Q) from The Globe and Mail including charting and trades.", "sitename": "The Globe and Mail", "date": "2023-09-09", "cleaned_text": "Data is being presented at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting MARLBOROUGH, Mass., May 18, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: [PHIO](#financial-modal)), a clinical stage biotechnology company whose proprietary INTASYL RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced pre-clinical data demonstrating that using INTASYL to silence TIGIT and CBL-B may be used to improve the anti-tumor response of NK cells, creating a more effective cell therapy for treating cancer. [Read "}